Gutenberg Open Science: Where will the next generation of medical treatments for overactive bladder syndrome come from?

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-6310

Full metadata record

DC Field	Value	Language
dc.contributor.author	Michel, Martin C.	-
dc.date.accessioned	2021-08-26T08:01:39Z	-
dc.date.available	2021-08-26T08:01:39Z	-
dc.date.issued	2020	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/6320	-
dc.description.abstract	This review article discusses the medical need for improved medical treatments of overactive bladder syndrome, and the hurdles and research required to address that need. Currently, few overactive bladder syndrome patients stay on long-term treatment, largely because efficacy expectations are not met, and tolerability is considered insufficient for the chronic treatment of a non-life-threatening condition. Therefore, a medical need exists for improved tolerability and, even more importantly, improved efficacy. It is unlikely that major improvements of efficacy and tolerability can be achieved within the currently approved drug classes. Work in experimental animals suggests that many causes of overactive bladder syndrome exist – each with a distinct pathophysiology. This makes it unlikely that a single medication can address the pathophysiology and treatment needs of all overactive bladder syndrome patients; accordingly, any medication will appear to have only moderate efficacy in the overall group of overactive bladder syndrome patients, even if it fully eliminates symptoms within a subset of patients. It is proposed that only identification of subsets of patients with a defined pathophysiology (and biomarkers thereof) will allow the development and use of targeted treatment that can be highly effective in such subsets.	en_GB
dc.language.iso	eng	de
dc.rights	CC BY-NC	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Where will the next generation of medical treatments for overactive bladder syndrome come from?	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-6310	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	International journal of urology	de
jgu.journal.volume	27	de
jgu.journal.issue	4	de
jgu.pages.start	289	de
jgu.pages.end	294	de
jgu.publisher.year	2020	-
jgu.publisher.name	Wiley-Blackwell	de
jgu.publisher.place	Oxford u.a.	de
jgu.publisher.uri	https://doi.org/10.1111/iju.14189	de
jgu.publisher.issn	1442-2042	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1111/iju.14189
jgu.organisation.ror	https://ror.org/023b0x485
Appears in collections:	JGU-Publikationen

Files in This Item:

	File	Description	Size	Format
	michel_martin_c.-where_will_the-20210826095649144.pdf		90.19 kB	Adobe PDF	View/Open

Show simple item record